Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Therapy for Newly Diagnosed High-risk Large B-cell Lymphoma
NCT04661020Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang University. Primary endpoint: Complete Remission Rate at 3 months. Started Dec 2020; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04661020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661020.